Back to search

Article

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)

2025-08-15

Abstract excerpt

<h4>Introduction</h4> Combining antibody-drug conjugates (ADCs) with radioimmunotherapy is a feasible and highly promising approach for treating HER2-positive patients, offering a potential paradigm for pan-cancer therapy. ADCs have demonstrated significant efficacy in cancers expressing human epidermal growth factor receptor 2 (HER2), independent of the tumor’s tissue of origin. Preclinical studies suggest that...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5a2eaf69-dd11-5401-860c-3232c0e27200
DOI
10.1101/2025.08.13.25333549
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)DOI 10.1101/2025.08.13.25333549
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity
Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity
KN026, a Bispecific Anti-HER2 Antibody, Combined with KN046, an Anti-CTLA-4/PD-L1 Antibody, in Patients with HER2-positive Advanced Gastrointestinal Cancer: a multicenter, open-label, nonrandomized, phase Ib studySemantic proximity
[Recent Advances in the Treatment of HER2-Altered Solid Tumors].Semantic proximity
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaSemantic proximity
<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity
Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.Semantic proximity
Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity
Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.Semantic proximity
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Semantic proximity
Phase 1 Dose Escalation Study of Seribantumab (MM-121), an anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid TumorsSemantic proximity
The Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast Cancer: A Multicenter Real-World Study from TurkeySemantic proximity
Select a neighboring publication to make it the new centre.